Crestpoint Capital Management Has Raised By $550,000 Its Bristol (BMY) Holding; Synergy Pharmaceuticals (SGYP)’s Sentiment Is 1.9

December 12, 2017 - By Dolores Ford

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. The company has market cap of $474.82 million. The Company’s lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. It currently has negative earnings. The firm also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

Crestpoint Capital Management Llc increased Bristol (BMY) stake by 45.66% reported in 2017Q2 SEC filing. Crestpoint Capital Management Llc acquired 10,000 shares as Bristol (BMY)’s stock declined 1.04%. The Crestpoint Capital Management Llc holds 31,900 shares with $1.78 million value, up from 21,900 last quarter. Bristol now has $103.96B valuation. The stock increased 0.79% or $0.5 during the last trading session, reaching $63.52. About 3.04M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since December 12, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Investors sentiment increased to 1.03 in Q2 2017. Its up 0.08, from 0.95 in 2017Q1. It increased, as 78 investors sold BMY shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. Pnc Financial Services Grp Inc Incorporated stated it has 0.37% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Oppenheimer Communications invested in 358,509 shares. Commonwealth Of Pennsylvania School Empls Retrmt Systems has 0.1% invested in Bristol-Myers Squibb Company (NYSE:BMY). Dodge & Cox has invested 1.39% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Maryland Cap has invested 0.15% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Tctc Holdings holds 1.21% or 317,981 shares in its portfolio. Moreover, Private Wealth Advsr has 0.12% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 4,916 shares. Family Cap Tru invested in 3,000 shares. M&R Capital reported 30,520 shares. Moreover, New York State Common Retirement Fund has 0.33% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 4.48 million shares. Nordea Management owns 0.1% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 737,268 shares. Gradient Invs Ltd Liability Com reported 0.03% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Davis R M stated it has 0.05% in Bristol-Myers Squibb Company (NYSE:BMY). Cacti Asset Limited Liability Company holds 0.16% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 32,680 shares. Papp L Roy & invested in 6,900 shares.

Crestpoint Capital Management Llc decreased Tribune Media stake by 26,800 shares to 8,300 valued at $338,000 in 2017Q2. It also reduced Jetblue Airways (NASDAQ:JBLU) stake by 17,800 shares and now owns 71,300 shares. Kraft Heinz was reduced too.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 69 analyst reports since July 28, 2015 according to SRatingsIntel. UBS maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, October 6 with “Buy” rating. Jefferies maintained it with “Hold” rating and $68.0 target in Thursday, November 16 report. On Friday, December 18 the stock rating was initiated by Atlantic Securities with “Underweight”. As per Thursday, July 14, the company rating was maintained by Jefferies. Citigroup maintained it with “Buy” rating and $72.0 target in Wednesday, October 25 report. The company was upgraded on Monday, December 19 by Jefferies. The company was initiated on Wednesday, April 26 by Robert W. Baird. The rating was maintained by Leerink Swann with “Buy” on Thursday, July 27. SunTrust maintained the shares of BMY in report on Monday, October 16 with “Hold” rating. As per Friday, April 29, the company rating was maintained by Barclays Capital.

The stock increased 2.39% or $0.045 during the last trading session, reaching $1.925. About 5.97 million shares traded. Synergy Pharmaceuticals Inc. (SGYP) has risen 24.44% since December 12, 2016 and is uptrending. It has outperformed by 7.74% the S&P500.

Great Point Partners Llc holds 5.76% of its portfolio in Synergy Pharmaceuticals Inc. for 7.22 million shares. Trellus Management Company Llc owns 345,000 shares or 2.25% of their US portfolio. Moreover, Armistice Capital Llc has 1.13% invested in the company for 2.00 million shares. The New York-based Orbimed Advisors Llc has invested 0.99% in the stock. Cormorant Asset Management Llc, a Massachusetts-based fund reported 1.20 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com